Tampa, FL (PRWEB) June 23, 2008
Xcelience, a contract research organization specializing in early drug development, recently announced the addition of Paul F. Skultety, Ph.D. to its executive management team. The company has broadened its expertise by appointing Dr. Skultety Director of Pharmaceutical Development Services. In this role, he oversees Xcelience's preformulation, analytical and formulation services.
An industry veteran, Skultety has over 26 years experience in pharmaceutical research and formulation development. He has held senior executive positions such as Vice President of Scientific Development at Aptuit Inc., Vice President of Pharmaceutics at Quintiles, and Director of Solids Formulations Development at Hoechst Marion Roussel (formerly Marion Merrill Dow and Marion Labs). He began his career in 1982 as a research pharmacist for Abbott Laboratories.
"Paul brings a wealth of experience and leadership to Xcelience. He is focused and realizes what it takes to work in the demanding customer services arena that we face everyday and he still enjoys it," stated Derek G. Hennecke, President and CEO.
Skultety's unique background in pharmaceutical formulation compliments Xcelience's diverse offerings to sponsors. It expands the company's team structure and ability to become a direct extension of sponsors' laboratories.
"Paul's knowledge truly strengthens Xcelience's arsenal of services for our clients," said Randall H. Guthrie, Vice President. "We look forward to his insights and leadership."
In addition, Skultety currently has nine registered patents with the United States Patent and Trademark Office related to formulation and pharmaceutical composition. He has spearheaded over 17 published articles and presentations and is a member of the American Association of Pharmaceutical Sciences (AAPS) and the Controlled Release Society.
Xcelience is the premier source for unsurpassed quality in drug development services. The company brings together the industry's most experienced and talented scientists, consistently and efficiently moving compounds through the research and development continuum to regulatory approval.
Since 1997, the Tampa-based laboratory has been developing formulations for clients throughout the pharmaceutical industry. Xcelience's unique corporate structure creates project teams that work intensively with each client, bringing an extension of their own organization into the Xcelience lab. The lab uses only state-of-the-art equipment, highlighted by the patented Xcelodose® which fills API directly to capsules (Xcelodose is a registered trademark of Capsugel BVBA). This and other technologies give Xcelience unparalleled speed to market without compromising its absolute commitment to quality.